Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
作者信息
Shapiro Lauren C, Mustafa Jennat, Lombardo Amanda, Khatun Fariha, Joseph Felisha, Gillick Kailyn, Naik Anjali, Elkind Richard, Abreu Michelly, Fehn Karen, de Castro Alyssa, Pradhan Kith, Binakaj Donika, Nelson Randin, Paroder Monika, Uehlinger Joan, Gritsman Kira, Alejandro Sica R, Kornblum Noah, Shastri Aditi, Mantzaris Ioannis, Bachier-Rodriguez Lizamarie, Verma Amit, Braunschweig Ira, Goldfinger Mendel
机构信息
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Department of Pharmacy, Montefiore Medical Center, Bronx, NY, USA.
出版信息
Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. doi: 10.1038/s41409-021-01280-3. Epub 2021 Apr 12.
PMID:33846558
Abstract
摘要
相似文献
1
Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.阿基仑赛注射液用于老年城市间人群复发/难治性大B细胞淋巴瘤的安全性
Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. doi: 10.1038/s41409-021-01280-3. Epub 2021 Apr 12.
2
Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.axi-cel（阿基仑赛）治疗复发难治性弥漫性大B细胞淋巴瘤后的迟发性神经毒性
Bone Marrow Transplant. 2021 Mar;56(3):683-685. doi: 10.1038/s41409-020-01029-4. Epub 2020 Aug 11.
3
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
4
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.嵌合抗原受体 T 细胞疗法 Axicabtagene Ciloleucel 治疗大 B 细胞淋巴瘤的研发与应用：综述。
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
5
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.阿基仑赛注射液用于既往接受过不同的靶向CD19嵌合抗原受体T细胞疗法治疗的复发或难治性淋巴瘤。
Blood Adv. 2020 Oct 13;4(19):4869-4872. doi: 10.1182/bloodadvances.2020002292.
6
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.阿基仑赛注射液：嵌合抗原受体 T 细胞治疗复发/难治性大 B 细胞淋巴瘤的临床数据。
Ann Pharmacother. 2021 Mar;55(3):390-405. doi: 10.1177/1060028020944233. Epub 2020 Jul 22.
7
Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.阿基仑赛嵌合抗原受体T细胞疗法治疗继发中枢神经系统受累的淋巴瘤
Mayo Clin Proc. 2019 Nov;94(11):2361-2364. doi: 10.1016/j.mayocp.2019.09.006.
8
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.EMA 对 Axicabtagene Ciloleucel（Yescarta）治疗弥漫性大 B 细胞淋巴瘤的审查。
Oncologist. 2020 Oct;25(10):894-902. doi: 10.1634/theoncologist.2019-0646. Epub 2020 Apr 27.
9
Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.阿基仑赛注射液用于完全代谢缓解的复发或难治性大B细胞淋巴瘤患者。
Haematologica. 2023 Apr 1;108(4):1163-1167. doi: 10.3324/haematol.2022.281954.
10
Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".致编辑的信：关于“阿基仑赛注射液与替雷利珠单抗注射液在复发/难治性大B细胞淋巴瘤中的疗效、安全性及输注前期比较”
Biol Blood Marrow Transplant. 2020 Dec;26(12):e333-e334. doi: 10.1016/j.bbmt.2020.08.032. Epub 2020 Sep 18.
Zotero 插件